Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Published: July 2010

Open Access Gateway

Gene Expression-Based Approaches in Differentiation of Metastases and Second Primary Tumour

Vooder T.a, b · Välk K.a · Kolde R.c · Roosipuu R.e · Vilo J.c · Metspalu A.a, d

Author affiliations

aInstitute of Molecular and Cell Biology, University of Tartu and Estonian Biocentre, bLung Clinic, Faculty of Medicine, cInstitute of Computer Science and dEstonian Genome Center, University of Tartu, eDepartment of Pathology, Tartu University Hospital, Tartu, Estonia

Corresponding Author

Andres Metspalu

Institute of Molecular and Cell Biology, University of Tartu and Estonian Biocentre Riia St. 23

Tartu 51010 (Estonia)

Tel. +372 737 5029, Fax +372 742 0286, E-Mail andres@ebc.ee

Related Articles for ""

Case Rep Oncol 2010;3:255–261

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


A 64-year-old male patient was diagnosed with 3 consecutive non-small cell lung carcinomas (NSCLC). In the current study, we applied whole-genome gene expression analysis to control, primary and locally recurrent cancer, and supposed metastasis samples of a single patient. According to our knowledge, there are no published papers describing the gene expression profiles of a single patient’s squamous cell lung cancers. As the histology and differentiation grade of the primary cancer and the supposed metastasis differed minimally, but local recurrence was poorly differentiated, molecular profiling of the samples was carried out in order to confirm or reject the hypothesis of second primary cancer. Principal component analysis of the gene expression data revealed distinction of the local recurrence. Gene ontology analysis showed no molecular characteristics of metastasis in the supposed metastasis. Gene expression analysis is valuable and can be supportive in decision-making of diagnostically complicated cancer cases.

© 2010 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Published: July 2010

Published online: July 21, 2010
Issue release date: April – August

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 1

eISSN: 1662-6575 (Online)

For additional information: https://www.karger.com/CRO

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.